BRCA1 and ovarian cancer: In 2014, the PARP inhibitor olaparib (LynparzaTM, AstraZeneca, Cambridge, UK) was approved for treating patients with relapsed ovarian cancer with germline BRCA1/2 mutations by the US Food and Drug Administration and European Medicines Agency and for patients with somatic BRCA1/2 mutations by the European Medicines Agency [6].